Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27821199 | 0.84 | POLB (0.59) | CYP1A2TSHRCYP4F2CYP4A11POLB | |
| SCHEMBL28859675 | 0.83 | CYP1A2 (0.64) | CYP1A2TSHRCYP2C19CYP4F2CYP4A11 | |
| SCHEMBL29099300 | 0.83 | CYP2D6 (0.43) | TSHRPOLBALDH1A1GAA | |
| SCHEMBL28929385 | 0.82 | MEN1 (0.52) | CYP1A2TSHRCYP2C19CYP4F2CYP4A11 | |
| SCHEMBL28243477 | 0.81 | HTR2A (0.44) | CYP1A2CYP2C19SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL29099218 | 0.79 | POLB (0.40) | CYP1A2TSHRCYP2C19POLBPPARG | |
| SCHEMBL28988456 | 0.79 | TSHR (0.46) | TSHRPPARGPPARAALDH1A1GAA | |
| SCHEMBL11104931 | 0.79 | ALDH1A1 (0.48) | CYP1A2TSHRCYP2C19CYP4F2CYP4A11 | |
| SCHEMBL17089903 | 0.78 | KMT2A (0.62) | CYP1A2POLB | |
| SCHEMBL24628375 | 0.78 | POLB (0.47) | CYP1A2TSHRPOLBPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110343042-B | Synthesis method of 2- ((9-hydrofluoren-9-yl) methyl) malonate | 温州大学 | 2021-10-08 | — | — | CN | disclosed |
| CN-110256247-B | Synthesis method of 2- ((9-hydrofluoren-9-yl) methyl) malonate | 温州大学 | 2021-09-21 | — | — | CN | disclosed |
| EP-2562156-B1 | COLCHICINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAID DERIVATIVES, AND PHARMACEUTICAL COMPOSITION COMPRISING SAID DERIVATIVES | ASAN FOUND (KR) | 2018-11-07 | — | — | EP | disclosed |
| CN-106062035-B | Polycondensation resin and optical film formed therefrom | 三菱化学株式会社 | 2018-05-29 | — | — | CN | disclosed |
| US-8927760-B2 | Colchicine derivatives or pharmaceutically acceptable salts thereof, method for preparing said derivatives, and pharmaceutical composition comprising said derivatives | THE ASAN FOUNDATION (KR) | 2015-01-06 | — | — | US | disclosed |
| US-8927760-B2 | Colchicine derivatives or pharmaceutically acceptable salts thereof, method for preparing said derivatives, and pharmaceutical composition comprising said derivatives | THE ASAN FOUNDATION (KR) | 2015-01-06 | — | — | US | disclosed |
| US-8927760-B2 | Colchicine derivatives or pharmaceutically acceptable salts thereof, method for preparing said derivatives, and pharmaceutical composition comprising said derivatives | THE ASAN FOUNDATION (KR) | 2015-01-06 | — | — | US | disclosed |
| EP-2562156-A2 | COLCHICINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAID DERIVATIVES, AND PHARMACEUTICAL COMPOSITION COMPRISING SAID DERIVATIVES | The Asan Foundation (KR) | 2013-02-27 | — | — | EP | disclosed |
| EP-2562156-A2 | COLCHICINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAID DERIVATIVES, AND PHARMACEUTICAL COMPOSITION COMPRISING SAID DERIVATIVES | The Asan Foundation (KR) | 2013-02-27 | — | — | EP | disclosed |
| US-20130011417-A1 | COLCHICINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAID DERIVATIVES, AND PHARMACEUTICAL COMPOSITION COMPRISING SAID DERIVATIVES | THE ASAN FOUNDATION (KR) | 2013-01-10 | — | — | US | disclosed |
| US-20130011417-A1 | COLCHICINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAID DERIVATIVES, AND PHARMACEUTICAL COMPOSITION COMPRISING SAID DERIVATIVES | THE ASAN FOUNDATION (KR) | 2013-01-10 | — | — | US | disclosed |
| US-20130011417-A1 | COLCHICINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAID DERIVATIVES, AND PHARMACEUTICAL COMPOSITION COMPRISING SAID DERIVATIVES | THE ASAN FOUNDATION (KR) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130011417-A1 | COLCHICINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAID DERIVATIVES, AND PHARMACEUTICAL COMPOSITION COMPRISING SAID DERIVATIVES | MYD88, IL5, NOD1 | CYP1A2 142/4885TSHR 4642/4885CYP2C19 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.